Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:ARDX NASDAQ:KRYS NASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$44.72+1.6%$49.62$21.34▼$58.40$3.58B-0.24819,256 shs2.34 million shsARDXArdelyx$6.52-0.8%$5.12$3.21▼$7.18$1.57B0.743.39 million shs3.01 million shsKRYSKrystal Biotech$150.27+0.3%$146.65$122.80▼$207.84$4.35B0.66254,453 shs324,265 shsPCVXVaxcyte$33.02+2.7%$33.22$27.66▼$121.06$4.29B1.041.48 million shs1.38 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+1.57%-4.30%-15.29%-17.61%+70.04%ARDXArdelyx-0.76%+2.52%+25.38%+77.17%+14.99%KRYSKrystal Biotech+0.35%+1.74%+10.49%+9.73%-19.19%PCVXVaxcyte+2.71%+7.24%+0.06%-10.73%-69.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$44.72+1.6%$49.62$21.34▼$58.40$3.58B-0.24819,256 shs2.34 million shsARDXArdelyx$6.52-0.8%$5.12$3.21▼$7.18$1.57B0.743.39 million shs3.01 million shsKRYSKrystal Biotech$150.27+0.3%$146.65$122.80▼$207.84$4.35B0.66254,453 shs324,265 shsPCVXVaxcyte$33.02+2.7%$33.22$27.66▼$121.06$4.29B1.041.48 million shs1.38 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+1.57%-4.30%-15.29%-17.61%+70.04%ARDXArdelyx-0.76%+2.52%+25.38%+77.17%+14.99%KRYSKrystal Biotech+0.35%+1.74%+10.49%+9.73%-19.19%PCVXVaxcyte+2.71%+7.24%+0.06%-10.73%-69.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$81.1481.45% UpsideARDXArdelyx 3.10Buy$11.7079.45% UpsideKRYSKrystal Biotech 2.88Moderate Buy$210.3840.00% UpsidePCVXVaxcyte 3.13Buy$130.00293.70% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, PCVX, AKRO, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.009/3/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$14.009/2/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy8/22/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$219.00 ➝ $216.008/22/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$240.008/7/2025PCVXVaxcyteCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$8.00 ➝ $9.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$12.008/5/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00 ➝ $12.008/5/2025ARDXArdelyxWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.00 ➝ $14.008/5/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$176.00 ➝ $166.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AARDXArdelyx$333.61M4.71N/AN/A$0.73 per share8.93KRYSKrystal Biotech$290.52M14.97$4.64 per share32.40$32.90 per share4.57PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)ARDXArdelyx-$39.14M-$0.23N/A21.03N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.9230.5414.91N/A40.85%15.21%13.81%11/3/2025 (Estimated)PCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)Latest ARDX, PCVX, AKRO, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AARDXArdelyxN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0212.6612.66ARDXArdelyx1.444.304.03KRYSKrystal BiotechN/A9.689.33PCVXVaxcyteN/A11.1111.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AARDXArdelyx58.92%KRYSKrystal Biotech86.29%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%ARDXArdelyx4.80%KRYSKrystal Biotech13.70%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableARDXArdelyx90240.98 million229.42 millionOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionablePCVXVaxcyte160129.82 million125.80 millionOptionableARDX, PCVX, AKRO, and KRYS HeadlinesRecent News About These CompaniesEventide Asset Management LLC Purchases 86,776 Shares of Vaxcyte, Inc. $PCVXSeptember 6 at 8:44 AM | marketbeat.comCormorant Asset Management LP Reduces Stock Position in Vaxcyte, Inc. $PCVXSeptember 6 at 7:45 AM | marketbeat.comAllostery Investments LP Buys New Position in Vaxcyte, Inc. $PCVXSeptember 5 at 6:54 AM | marketbeat.comADAR1 Capital Management LLC Buys New Shares in Vaxcyte, Inc. $PCVXSeptember 4 at 7:41 AM | marketbeat.comFirst Light Asset Management LLC Invests $3.57 Million in Vaxcyte, Inc. $PCVXSeptember 4 at 7:27 AM | marketbeat.comRA Capital Management L.P. Grows Stake in Vaxcyte, Inc. $PCVXSeptember 4 at 7:16 AM | marketbeat.comBaker BROS. Advisors LP Purchases 592,000 Shares of Vaxcyte, Inc. $PCVXSeptember 4 at 6:27 AM | marketbeat.comVaxcyte advances VAX-31 infant Phase 2 studySeptember 3 at 7:48 PM | msn.comVaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized DoseSeptember 3 at 7:30 AM | globenewswire.comVaxcyte, Inc. $PCVX Stock Position Raised by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Shares Purchased by Raymond James Financial Inc.September 2, 2025 | marketbeat.comDriehaus Capital Management LLC Has $40.06 Million Stock Position in Vaxcyte, Inc. $PCVXAugust 31, 2025 | marketbeat.comRafferty Asset Management LLC Trims Holdings in Vaxcyte, Inc. $PCVXAugust 31, 2025 | marketbeat.comNorthern Trust Corp Sells 37,045 Shares of Vaxcyte, Inc. $PCVXAugust 31, 2025 | marketbeat.comWalleye Capital LLC Trims Stock Position in Vaxcyte, Inc. $PCVXAugust 29, 2025 | marketbeat.comComerica Bank Purchases 21,091 Shares of Vaxcyte, Inc. $PCVXAugust 28, 2025 | marketbeat.com100,100 Shares in Vaxcyte, Inc. $PCVX Acquired by Jump Financial LLCAugust 28, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Down 4.9% - What's Next?August 27, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Trims Holdings in Vaxcyte, Inc. $PCVXAugust 27, 2025 | marketbeat.comVaxcyte, Inc. $PCVX Shares Sold by American Century Companies Inc.August 26, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Cuts Stock Position in Vaxcyte, Inc. $PCVXAugust 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, PCVX, AKRO, and KRYS Company DescriptionsAkero Therapeutics NASDAQ:AKRO$44.72 +0.69 (+1.57%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$45.27 +0.55 (+1.24%) As of 09/5/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Ardelyx NASDAQ:ARDX$6.52 -0.05 (-0.76%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.52 +0.01 (+0.08%) As of 09/5/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Krystal Biotech NASDAQ:KRYS$150.27 +0.52 (+0.35%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$150.54 +0.26 (+0.18%) As of 09/5/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Vaxcyte NASDAQ:PCVX$33.02 +0.87 (+2.71%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$33.02 +0.00 (+0.02%) As of 09/5/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
